Abstract
BAFF system plays an essential role in B cells homeostasis and tolerance, although it has widely not been tested in transplantation with doubtful results. The main purpose was to study the BAFF soluble forms and their correlation with acute rejection (AR) and donor-specific antibodies production. Serum levels of BAFF, APRIL, and soluble forms of their receptors were analyzed in renal recipients with and without acute rejection (AR/NAR) appearance. All molecules were evaluated at pre- and post-transplantation. sTACI showed a significant correlation with BAFF and sR-BAFF levels, and sBCMA also showed a positive correlation with sAPRIL levels. A significant increase in sAPRIL levels in patients suffering AR was also found, and ROC curves analysis showed an AUC = 0.724, a concentration of 6.05 ng/ml (sensitivity: 66.7%; specificity: 73.3%), the best cutoff point for predicting AR. In the post-transplant dynamics of sAPRIL levels in the longitudinal cohort, we observed a significant decrease at 3 and 6 month post-transplantation compared to pretransplantation status. We also observed that recipients with high pre-transplant levels of sAPRIL generated antibodies earlier than those with lower sAPRIL levels, although their long-term post-transplantation was not different. Our results show that elevated serum levels of APRIL may be helpful as a biomarker for the diagnosis of AR, although the longitudinal study shows that it is not helpful as a prognostic biomarker.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Afzali S, Salehi S, Shahi A et al (2021) Investigating the role of BAFF and its receptors in renal transplant recipients with chronic antibody-mediated rejection. J Immunol Res 2021:6654992. https://doi.org/10.1155/2021/6654992
Alfaro R, Jaouad EKEB, Llorente S et al (2021a) Personalized medicine for kidney transplantation: association of graft survival and acute transplant rejection with genetic variation in B cell activating factor system signaling. OMICS 25:725–737. https://doi.org/10.1089/OMI.2021.0099
Alfaro R, Legaz I, González-Martínez G et al (2021b) Monitoring of B cell in kidney transplantation: development of a novel clusters analysis and role of transitional B cells in transplant outcome. Diagnostics 11:641. https://doi.org/10.3390/diagnostics11040641
Alfaro R, Legaz I, Jimenez-Coll V et al (2021c) MicroRNA expression changes in kidney transplant: diagnostic efficacy of miR-150-5p as potential rejection biomarker, pilot study. J Clin Med 10:2748. https://doi.org/10.3390/JCM10132748
Benson MJ, Dillon SR, Castigli E et al (2008) Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 180:3655–3659. https://doi.org/10.4049/JIMMUNOL.180.6.3655
Bijkerk R, Florijn BW, Khairoun M et al (2017) Acute rejection after kidney transplantation associates with circulating microRNAs and vascular injury. Transpl Direct 3:e174. https://doi.org/10.1097/TXD.0000000000000699
Bloom DD, Reshetylo S, Nytes C et al (2018) Blockade of BAFF receptor BR3 on T cells enhances their activation and cytotoxicity. J Immunother 41:213. https://doi.org/10.1097/CJI.0000000000000209
Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18:263–275. https://doi.org/10.1016/J.SMIM.2006.04.006
Calame KL (2001) Plasma cells: finding new light at the end of B cell development. Nat Immunol 212(2):1103–1108. https://doi.org/10.1038/ni1201-1103
Chasset F, de Masson A, Le Buanec H et al (2016) APRIL levels are associated with disease activity in human chronic graft-versus-host disease. Haematologica 101:e312. https://doi.org/10.3324/HAEMATOL.2016.145409
Chen M, Lin X, Liu Y et al (2014) The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev 25:301. https://doi.org/10.1016/J.CYTOGFR.2013.12.011
Clark WB, Brown-Gentry KD, Crawford DC et al (2011) Genetic variation in recipient B-cell activating factor modulates phenotype of GVHD. Blood 118:1140–1144. https://doi.org/10.1182/blood-2010-09-310011
Cohen D, Colvin RB, Daha MR et al (2012) Pros and cons for C4d as a biomarker. Kidney Int 81:628–639. https://pubmed.ncbi.nlm.nih.gov/22297669/.
Darce JR, Arendt BK, Wu X et al (2007) Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 179:7276–7286. https://doi.org/10.4049/jimmunol.179.11.7276
Daridon C, Youinou P, Pers JO (2008) BAFF, APRIL, TWE-PRIL: who’s who? Autoimmun Rev 7:267–271. https://doi.org/10.1016/J.AUTREV.2007.05.002
Davidson A (2010) Targeting BAFF in autoimmunity. Curr Opin Immunol 22:732–739. https://pubmed.ncbi.nlm.nih.gov/20970975/.
Friebus-Kardash J, Wilde B, Keles D et al (2018) Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival. Transpl Immunol 47:10–17. https://doi.org/10.1016/J.TRIM.2017.12.004
Galián JA, Mrowiec A, Muro M (2016) Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and future. Expert Opin Ther Targets 20:859–867. https://doi.org/10.1517/14728222.2016.1135904
Ghermezi M, Li M, Vardanyan S et al (2017) Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102:785. https://doi.org/10.3324/HAEMATOL.2016.150896
Grenzi PC, Campos ÉF, Silva HT et al (2015) Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation. Transpl Immunol 32:61–65. https://doi.org/10.1016/J.TRIM.2015.02.004
Gutierrez MJ, Desiderio SV, Wang NY et al (2019) Soluble markers of antibody secreting cell function as predictors of infection risk in rheumatoid arthritis. J Immunol Res 2019:3658215. https://doi.org/10.1155/2019/3658215
Halloran PF, Halloran PF (2010) T cell-mediated rejection of kidney transplants: a personal viewpoint. Am J Transpl 10:1126–1134. https://doi.org/10.1111/J.1600-6143.2010.03053.X
Harris DP, Haynes L, Sayles PC et al (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1:475–482. https://doi.org/10.1038/82717
Hoffmann FS, Kuhn P-H, Laurent SA et al (2015) The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 194:542–552. https://doi.org/10.4049/jimmunol.1402070
Hua C, Audo R, Yeremenko N et al (2016) A proliferation inducing ligand (APRIL) promotes IL-10 production and regulatory functions of human B cells. J Autoimmun 73:64–72. https://doi.org/10.1016/J.JAUT.2016.06.002
Irure-Ventura J, Segundo DS, Rodrigo E et al (2020) High pretransplant BAFF levels and B-cell subset polarized towards a memory phenotype as predictive biomarkers for antibody-mediated rejection. Int J Mol Sci 21:779. https://doi.org/10.3390/IJMS21030779
Jo HA, Han SS, Lee S et al (2019) The association of tumor necrosis factor superfamily 13 with recurrence of immunoglobulin A nephropathy in living related kidney transplantation. BMC Nephrol 20:33. https://doi.org/10.1186/S12882-019-1222-4/FIGURES/2
Krupa A, Jenkins R, Luo DD et al (2010) Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol 21:438–447. https://doi.org/10.1681/ASN.2009050530
Kwun J, Page E, Hong JJ et al (2015) Neutralizing BAFF/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model. Am J Transpl 15:815–822. https://doi.org/10.1111/ajt.13045
Laurent SA, Hoffmann FS, Kuhn PH et al (2015) γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333. https://doi.org/10.1038/ncomms8333
Legaz I, Bernardo MV, Alfaro R et al (2021) PCR array technology in biopsy samples identifies up-regulated mTOR pathway genes as potential rejection biomarkers after kidney transplantation. Front Med 8:547849. https://doi.org/10.3389/fmed.2021.547849
Legaz I, Boix F, López M et al (2020) Influence of preformed antibodies in liver transplantation. J Clin Med 9:708. https://doi.org/10.3390/jcm9030708
Luu VP, Vazquez MI, Zlotnik A (2014) B cells participate in tolerance and autoimmunity through cytokine production. Autoimmunity 47:1–12. https://pubmed.ncbi.nlm.nih.gov/24245950/.
Min JW, Kim KW, Kim BM et al (2016) Clinical significance of pre-and post-transplant BAFF levels in kidney transplant recipients. PLoS One 11:e0162964. https://doi.org/10.1371/journal.pone.0162964
Nafar M, Farrokhi F, Vaezi M et al (2009) Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 41:687–693. https://doi.org/10.1007/S11255-008-9505-X/FIGURES/2
Nelson PJ, Krensky AM (2001) Chemokines, chemokine receptors, and allograft rejection. Immunity 14:377–386. https://pubmed.ncbi.nlm.nih.gov/11336683/.
Newell KA, Asare A, Sanz I et al (2015) Longitudinal studies of a B cell-derived signature of tolerance in renal transplant recipients. Am J Transpl 15:2908–2920. https://doi.org/10.1111/ajt.13480
Ng LG, Sutherland APR, Newton R et al (2004) B cell-activating factor belonging to the TNF family (BAFF)-R is the principal baff receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 173:807–817. https://doi.org/10.4049/JIMMUNOL.173.2.807
Pelzl S, Opelz G, Daniel V et al (2003) Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75:421–423. https://doi.org/10.1097/01.TP.0000044702.18327.66
Pongpirul W, Chancharoenthana W, Pongpirul K et al (2018) B-cell activating factor, a predictor of antibody mediated rejection in kidney transplantation recipients. Nephrology 23:169–174. https://doi.org/10.1111/nep.12972
Sakai J, Akkoyunlu M (2017) The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev 30:991–1014. https://doi.org/10.1128/CMR.00046-17
Shimizu T, Toma H, Hayakawa N et al (2016) Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation. Nephrology 21:26–30. https://doi.org/10.1111/NEP.12766
Slavcev A, Brozova J, Slatinska J et al (2016) Soluble BAFF cytokine levels and antibody-mediated rejection of the kidney allograft. Arch Immunol Ther Exp 64(suppl 1):47–53. https://doi.org/10.1007/s00005-016-0428-4
Smulski CR, Kury P, Seidel LM et al (2017) BAFF- and TACI-dependent processing of BAFFR by ADAM proteases regulates the survival of B cells. Cell Rep 18:2189–2202. https://doi.org/10.1016/J.CELREP.2017.02.005
Solgi G, Furst D, Mytilineos J et al (2012) Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA. Transpl Immunol 26:81–87. https://doi.org/10.1016/J.TRIM.2011.12.002
Süsal C, Pelzl S, Döhler B, Opelz G (2002) Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13:1650–1656. https://doi.org/10.1097/01.ASN.0000014256.75920.5B
Tai YT, Lin L, Xing L et al (2019) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia 33:426–438. https://doi.org/10.1038/s41375-018-0242-6
Thaler FS, Laurent SA, Huber M et al (2017) Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. Neuro Oncol 19:1618–1627. https://doi.org/10.1093/NEUONC/NOX097
Thibault-Espitia A, Foucher Y, Danger R et al (2012) BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Am J Transpl 12:2754–2762. https://doi.org/10.1111/j.1600-6143.2012.04194.x
Wang D, Wu GJ, Wu WZ et al (2007) Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection. Transpl Immunol 17:278–282. https://doi.org/10.1016/J.TRIM.2007.02.001
Wang XZ, Wan Z, Xue WJ et al (2019) B-cell activating factor predicts acute rejection risk in kidney transplant recipients: a 6-month follow-up study. Front Immunol 10:1046. https://doi.org/10.3389/FIMMU.2019.01046/BIBTEX
Xu H, He X, Xu R (2018) B cell activating factor, renal allograft antibody-mediated rejection, and long-term outcome. J Immunol Res 2018:251801. https://doi.org/10.1155/2018/5251801
Yu G, Boone T, Delaney J et al (2000) APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 1:252–256. https://doi.org/10.1038/79802
Funding
Our work was possible thanks to support from Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness. Grant Number PI15/01370, P19/01194, and PI20/00050 and co-funding the European Union with the European Fund of Regional Development (FEDER) with the principle of “A manner to build Europe”.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that this research was conducted without any commercial or financial relationships construed as a potential conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Alfaro, R., Llorente, S., Martinez, P. et al. Monitoring of Soluble Forms of BAFF System (BAFF, APRIL, sR-BAFF, sTACI and sBCMA) in Kidney Transplantation. Arch. Immunol. Ther. Exp. 70, 21 (2022). https://doi.org/10.1007/s00005-022-00659-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00005-022-00659-4